Pharmagreen Biotech Inc. (PHBI)
OTCMKTS · Delayed Price · Currency is USD
0.0007
-0.0001 (-6.67%)
Jul 27, 2026, 9:53 AM EST
Pharmagreen Biotech Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 |
Cash & Equivalents | 0 | 0 | 0 | 0.01 | 0.03 | 0.01 |
Cash & Short-Term Investments | 0 | 0 | 0 | 0.01 | 0.03 | 0.01 |
Cash Growth | 21.94% | -77.99% | -84.36% | -68.32% | 107.44% | -80.54% |
Accounts Receivable | 0 | 0 | 0 | - | - | - |
Other Receivables | - | - | - | 0 | 0 | 0 |
Receivables | 0.09 | 0 | 0 | 0 | 0 | 0 |
Inventory | 0.01 | 0.01 | 0.01 | - | - | - |
Prepaid Expenses | - | - | - | 0.2 | 0.35 | 0.25 |
Other Current Assets | - | - | 0.02 | - | - | - |
Total Current Assets | 0.1 | 0.01 | 0.03 | 0.21 | 0.37 | 0.27 |
Total Assets | 0.1 | 0.1 | 0.12 | 0.21 | 0.37 | 0.27 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 |
Accounts Payable | 0.79 | 0.8 | 0.74 | 0.11 | 0.13 | 0.11 |
Accrued Expenses | 1.08 | 1.07 | 0.88 | 1.18 | 1.07 | 0.89 |
Short-Term Debt | 0.13 | 0.13 | 0.13 | 0.1 | 0.04 | 0.04 |
Current Portion of Long-Term Debt | 0.14 | 0.14 | 0.15 | 0.12 | 0.19 | 0.64 |
Other Current Liabilities | 0.27 | 1 | 0.31 | 0.41 | 0.59 | 1.49 |
Total Current Liabilities | 2.41 | 3.14 | 2.21 | 1.91 | 2.03 | 3.17 |
Long-Term Debt | 0.09 | 0.09 | 0.09 | 0.12 | 0.04 | 0.03 |
Total Liabilities | 2.5 | 3.23 | 2.3 | 2.03 | 2.07 | 3.2 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 |
Common Stock | 0.66 | 0.66 | 0.57 | 0.44 | 0.38 | 0.1 |
Additional Paid-In Capital | 10.32 | 10.32 | 10.36 | 10.26 | 9.68 | 3.97 |
Retained Earnings | -13.51 | -14.15 | -13.14 | -12.57 | -11.7 | -7.17 |
Comprehensive Income & Other | 0.18 | 0.08 | 0.08 | 0.09 | -0.01 | 0.22 |
Total Common Equity | -2.35 | -3.09 | -2.13 | -1.78 | -1.65 | -2.89 |
Minority Interest | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
Shareholders' Equity | -2.4 | -3.13 | -2.18 | -1.82 | -1.69 | -2.93 |
Total Liabilities & Equity | 0.1 | 0.1 | 0.12 | 0.21 | 0.37 | 0.27 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 |
Total Debt | 0.35 | 0.36 | 0.37 | 0.34 | 0.27 | 0.71 |
Net Cash (Debt) | -0.35 | -0.36 | -0.37 | -0.33 | -0.24 | -0.7 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
Filing Date Shares Outstanding | 663.65 | 663.65 | 663.65 | 454.76 | 385.17 | 245.61 |
Total Common Shares Outstanding | 663.65 | 663.65 | 573.46 | 442.26 | 381.17 | 95.81 |
Working Capital | -2.31 | -3.13 | -2.18 | -1.7 | -1.65 | -2.9 |
Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.03 |
Tangible Book Value | -2.35 | -3.09 | -2.13 | -1.78 | -1.65 | -2.89 |
Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.03 |